文献速递乳腺癌放疗放疗物理与技术

DCE-MRI评估早期乳腺癌新辅助SABR反应:单次与三次分割及成像延迟比较

DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR.
PubMed 文献 · Clin Transl Radiat Oncol · 2019-12-25

本研究对17例早期乳腺癌患者在新辅助立体定向消融放疗(SABR)前后行DCE-MRI,比较单次21 Gy与三次30 Gy分割及放疗后6-7天与16-19天成像延迟对动力学参数的影响。结果显示三次分割组SEV均下降,单次分割组多数SEV升高;Ktrans在单次组升高76%,三次组降低34%,提示三次分割后约2.5周成像可反映反应且减少急性效应干扰。

要点

  • 三次分割SABR后16-18天所有患者SEV下降,单次分割后6-7天所有患者SEV升高。
  • 单次分割组Ktrans平均升高76%(p=0.043),三次分割组降低34%(p=0.028)。
  • 单次分割后一周DCE-MRI可能过早,2.5周成像可减少急性效应混杂。

核心结论

  • 单次和三次分割SABR后约2.5周测量的动力学参数均可提示反应,但仅单次分割方案导致周围组织信号增强。
  • 单次分割SABR后一周行DCE-MRI可能过早评估反应,2.5周成像时间足够长以减少急性效应混杂。

研究设计与样本

  • 前瞻性研究纳入17例早期乳腺癌患者,在新辅助SABR前后行DCE-MRI。
  • 5例在21 Gy/1次后6-7天成像(组1),6例在21 Gy/1次后16-19天成像(组2),6例在30 Gy/3次(隔日)后16-18天成像(组3)。
  • DCE-MRI使用临床剂量一半的对比剂,采用信号增强阈值指标量化信号增强体积(SEV),用Tofts模型计算Ktrans和ve。
  • 使用Wilcoxon符号秩检验评估显著性。

主要发现

  • 组1所有患者和组2的4/6患者SABR后SEV升高,组3所有患者SEV下降。
  • 组1平均Ktrans升高76%(p=0.043),组2降低15%(p=0.028),组3降低34%(p=0.028)。
  • 组1的ve无显著变化(p=0.35),组2的ve升高24%(p=0.043),组3的ve呈升高趋势(23%,p=0.08)。

临床怎么用

  • 早期乳腺癌新辅助SABR后行DCE-MRI评估反应时,三次分割方案后约2.5周成像可减少急性效应干扰。
  • 单次分割SABR后一周内不宜用DCE-MRI评估反应,建议延迟至约2.5周。

局限性

  • 样本量小,各组仅5-6例,统计效能有限。
  • 未报告长期临床终点与影像参数的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the effect of dose fractionation and time delay post-neoadjuvant stereotactic ablative radiotherapy (SABR) on dynamic contrast-enhanced (DCE)-MRI parameters in early stage breast cancer patients. MATERIALS AND METHODS: DCE-MRI was acquired in 17 patients pre- and post-SABR. Five patients were imaged 6-7 days post-21 Gy/1fraction (group 1), six 16-19 days post-21 Gy/1fraction (group 2), and six 16-18 days post-30 Gy/3 fractions every other day (group 3). DCE-MRI scans were performed using half the clinical dose of contrast agent. Changes in the surrounding tissue were quantified using a signal-enhancement threshold metric that characterizes changes in signal-enhancement volume (SEV). Tumour response was quantified using Ktrans and ve (Tofts model) pre- and post-SABR. Significance was assessed using a Wilcoxin signed-rank test. RESULTS: All group 1 and 4/6 group 2 patients' SEV increased post-SABR. All group 3 patients' SEV decreased. The mean Ktrans increased for group 1 by 76% (p = 0.043) while group 2 and 3 decreased 15% (p = 0.028) and 34% (p = 0.028), respectively. For ve, there was no significant change in Group 1 (p = 0.35). Groups 2 showed an increase of 24% (p = 0.043), and Group 3 trended toward an increase (23%, p = 0.08). CONCLUSION: Kinetic parameters measured 2.5 weeks post-SABR in both single fraction and three fraction groups were indicative of response but only the single fraction protocol led to enhancement in the surrounding tissue. Our results also suggest that DCE-MRI one-week post-SABR may be too early for response assessment, at least for single fraction SABR, whereas 2.5 weeks appears sufficiently long to minimize confounding acute effects.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mouawad M, Biernaski H, Brackstone M, et al. DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR. Clin Transl Radiat Oncol. 2019. PMID: 32021911. doi:10.1016/j.ctro.2019.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。